Lundbeck/Otsuka Global Alliance Will Support Lundbeck's Move Into U.S. Psychiatry Market
This article was originally published in PharmAsia News
You may also be interested in...
Danish pharma increases investment in new product launches as it prepares for loss of patent protection on its lead product, escitalopram.
As lead drug Lexapro/Cipralex faces genericization, Lundbeck is counting on revenues from ongoing licensing deals to fill the $1 billion hole.
Ipsen is to restart a global Phase III study of palovarotene in an ultra-rare bone disorder after additional analyses of interim data, but a partial clinical hold of the compound's use in patients aged under 14 years of age remains in place.